机译:甲氨蝶呤在肥胖2型糖尿病患者中的功效:瘦素耐受性的细胞和分子途径
Division of Endocrinology, Diabetes, and Metabolism, Beth IsraelDeaconess Medical Center, Harvard Medical School, Boston, Massachusetts;
theLaboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Conisglio Nazionale delle Ricerche c/o Dipartimento diBiologia e Patologia Cellulare e Molecolare, Universita di Napoli FedericoII, Napoli, Italy;
Division of Endocrinology, Diabetes, and Metabolism, Beth IsraelDeaconess Medical Center, Harvard Medical School, Boston, Massachusetts;
Division of Endocrinology, Diabetes, and Metabolism, Beth IsraelDeaconess Medical Center, Harvard Medical School, Boston, Massachusetts;
Division of Endocrinology, Diabetes, and Metabolism, Beth IsraelDeaconess Medical Center, Harvard Medical School, Boston, Massachusetts;
Division of Endocrinology, Diabetes, and Metabolism, Beth IsraelDeaconess Medical Center, Harvard Medical School, Boston, Massachusetts;
Division of Endocrinology, Diabetes, and Metabolism, Beth IsraelDeaconess Medical Center, Harvard Medical School, Boston, Massachusetts;
theLaboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Conisglio Nazionale delle Ricerche c/o Dipartimento diBiologia e Patologia Cellulare e Molecolare, Universita di Napoli FedericoII, Napoli, Italy;
theLaboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Conisglio Nazionale delle Ricerche c/o Dipartimento diBiologia e Patologia Cellulare e Molecolare, Universita di Napoli FedericoII, Napoli, Italy;
Division of Endocrinology, Diabetes, and Metabolism, Beth IsraelDeaconess Medical Center, Harvard Medical School, Boston, Massachusetts;
Amgen, Inc., Thousand Oaks, California;
Division ofMinimally Invasive Surgery, Beth Israel Deaconess Medical Center, HarvardMedical School, Boston, Massachusetts;
Division of Endocrinology, Diabetes, and Metabolism, Beth IsraelDeaconess Medical Center, Harvard Medical School, Boston, Massachusetts,the Section of Endocrinology, Boston VA Healthcare System, Harvard Medical School, Boston,Massachusetts;
机译:甲氨蝶呤在肥胖2型糖尿病患者中的功效:瘦素耐受性的细胞和分子途径
机译:患有1型糖尿病患者的Metreleptin治疗的疗效和安全性:试验研究
机译:肥胖或脂肪营养不良患者与甲氨蝶呤治疗相关的免疫原性
机译:2型糖尿病患者ACE基因I / D多态性与肥胖
机译:在一个孤立的加拿大原住民社区中评估适应性及其与2型糖尿病,糖耐量受损和肥胖的关系。
机译:甲氨蝶呤在肥胖2型糖尿病患者中的功效:瘦素耐受性的细胞和分子途径
机译:甲氨蝶呤在肥胖2型糖尿病患者中的功效:瘦素耐受性的细胞和分子途径